Increased levels of the negative regulator of RAAS signaling, angiotensin-converting enzyme 2 (ACE2), is a biomarker for higher mortality rate and myocardial fibrosis in patients with CAVD (36). The gene discussed is ACE2; the disease is congenital bilateral aplasia of vas deferens from CFTR mutation.